Recent News

• 04.16.2025 - Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
• 04.01.2025 - Cardiol Therapeutics Announces Year-End 2024 Update on Operations
• 03.03.2025 - Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
• 02.20.2025 - Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science that Supports Development of its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
• 02.04.2025 - Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 11.18.2024 - Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Recent Filings

• 04.16.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.16.2025 - EX-99.1 EX-99.1
• 04.01.2025 - EX-99.1 EX-99.1
• 04.01.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.31.2025 - 40-F Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]
• 03.14.2025 - EX-99.1 EX-99.1
• 03.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.03.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.20.2025 - EX-99.1 EX-99.1